Cholangitis
Comorbidities
FDA approves Gilead’s Livdelzi for treatment of primary biliary cholangitis
Gilead’s Livdelzi, a selective peroxisome proliferator-activated receptor delta agonist, has received accelerated FDA approval for the treatment of primary biliary cholangitis, according to a company release.
CRC incidence significantly higher among patients with cryptogenic pyogenic liver abscess
Patients diagnosed with cryptogenic pyogenic liver abscess had a “significantly higher incidence” of colorectal cancer up to 3 years from diagnosis compared with matched controls, highlighting the importance of CRC screening, data showed.
VIDEO: Interim INTEGRIS-PSC trial results ‘promising’ in primary sclerosing cholangitis
BOSTON — Healio spoke with James L. Boyer, MD, FACEP, about interim results from the phase 2a INTEGRIS-PSC trial presented at The Liver Meeting, which showed bexotegrast reduced biomarkers of liver fibrosis vs. placebo.
‘Encouraging’ ELATIVE data for elafibranor may spark race for primary biliary cholangitis
Topline findings from the phase 3 ELATIVE trial showed that elafibranor improved cholestasis response in patients with primary biliary cholangitis, Ipsen and Genfit announced.
Ocaliva plus bezafibrate clears FDA orphan drug hurdle for primary biliary cholangitis
The FDA granted Intercept Pharmaceuticals orphan drug designation for the fixed-dose combination of obeticholic acid and bezafibrate intended for treatment of patients with primary biliary cholangitis.